HAMILTON, Bermuda, Sept. 17 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) announced today that LEO Pharma A/S ("LEO") has received a non-final Action Closing Prosecution from the U.S. Patent and Trademark Office (the "USPTO"). In September 2006, the USPTO ordered a reexamination of LEO's US Patent No. 6,753,013 (the "013 Patent") in response to a request made by Galderma R&D. The 013 Patent covers TACLONEX and certain of LEO's products in development. Warner Chilcott markets and sells TACLONEX in the United States under a license agreement with LEO and has license rights to certain products in development.
In the non-final Action Closing Prosecution the patent examiner allowed the specific formulation claim for TACLONEX ointment, but rejected the remaining pending claims in the reexamination of LEO's 013 Patent. LEO intends to vigorously defend the 013 Patent and will file a response with the USPTO.
While we can offer no assurance as to the ultimate outcome of the reexamination proceedings, including any related appeals, Warner Chilcott continues to believe that LEO will succeed in maintaining the important elements of the patent protection for TACLONEX, particularly based on the timing, extent and quality of the development work conducted by LEO with vitamin D analogues in combination with corticosteroids.
About Warner Chilcott
Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the United States. WCRX-G
Read more on http://www.warnerchilcott.com.
|SOURCE Warner Chilcott Limited|
Copyright©2007 PR Newswire.
All rights reserved